|
||
Acetaminophen CODEINE JALINOUS Pregnancy |
||
Acetaminophen CODEINE JALINOUS crosses the placenta (Naga Rani 1989).
Based on epidemiological data, an increased risk of major congenital malformations has not been observed following maternal use of Acetaminophen CODEINE JALINOUS during pregnancy. Although not considered a major birth defect, an association between maternal Acetaminophen CODEINE JALINOUS use and cryptorchidism (undescended testis) has been observed (Fisher 2016; Jensen 2010; Kristensen 2011; Snijder 2012). The use of Acetaminophen CODEINE JALINOUS in normal doses during pregnancy is not associated with an increased risk of miscarriage or still birth; however, an increase in fetal death or spontaneous abortion may be seen following maternal overdose if treatment is delayed (Li 2003; Rebordosa 2009; Riggs 1989). Prenatal constriction of the ductus arteriosus has been noted in case reports following maternal use during the third trimester (Allegaert 2019); although this association was not confirmed in a large observational study (Dathe 2019), Acetaminophen CODEINE JALINOUS has been evaluated for the treatment of a persistent patent ductus arteriosus in preterm neonates (Terrin 2016). Additional adverse events such as wheezing and asthma in early childhood and adverse neurodevelopmental effects such as ADHD following in utero Acetaminophen CODEINE JALINOUS exposure have been evaluated in multiple studies; outcome information is inconclusive, and a causal association has not been established (Cheelo 2014; Fan 2017; Lourido-Cebreiro 2017; Scialli 2010; SMFM 2017). It should be noted that maternal fever is also associated with adverse fetal outcomes, including neural tube defects, oral clefts, and congenital heart defects. Treatment of maternal fever with an antipyretic may reduce these risks (Drier 2014).
Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of Acetaminophen CODEINE JALINOUS may be altered. Dose adjustments are not recommended (Kulo 2014). Acetaminophen CODEINE JALINOUS is considered appropriate for the treatment of pain and fever in pregnancy (SMFM 2017). Acetaminophen CODEINE JALINOUS may be used as part of a multimodal approach to pain relief following cesarean delivery (ACOG 209 2019), for the treatment of acute migraine in pregnant patients (Burch 2019; Hamilton 2019a; Marmura 2015) and is recommended for the treatment of fever in pregnant women diagnosed with influenza (ACOG 753 2018). Acetaminophen CODEINE JALINOUS is recommended to be used at the lowest effective dose for the shortest duration of time to effectively treat the mother and protect the health of the fetus (Kilcoyne 2017).
One small study has reported that following a 1000 mg dose of Acetaminophen CODEINE JALINOUS to nursing mothers, nursing infants receive less than 1.85% of the weight-adjusted maternal oral dose.
Aspirin is excreted into human milk in small amounts. Peak milk salicylate levels have been reported at nine hours after maternal dosing (and measured at 1.1 mg/dL). Use of large doses of aspirin can result in rashes, platelet abnormalities, and bleeding in nursing infants. Because of a single case report of metabolic acidosis, the American Academy of Pediatrics characterizes aspirin as a drug that has been "associated with significant effects on some nursing infants and should be given to nursing mothers with caution." Acetaminophen CODEINE JALINOUS is excreted into human milk in small concentrations. One case of a rash has been reported in a nursing infant. Acetaminophen CODEINE JALINOUS is considered compatible with breast-feeding by the American Academy of Pediatrics. Caffeine is excreted into human milk in small amounts. Adverse effects in the nursing infant are unlikely. However, irritability and poor sleep patterns have been reported in nursing infants. The amount of caffeine generally found in caffeinated beverages is considered to usually be compatible with breast-feeding by the American Academy of Pediatrics. Because caffeine is excreted into human milk and because caffeine is metabolized slowly by nursing infants, consumption of more than moderate levels of caffeine by nursing mothers is not recommended.
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|